Advances in the Management of Severe Asthma

 

 Buy Article Permissions and Reprints

Abstract

Severe asthma affects 5 to 10% of the asthma population but consumes a disproportionate amount of the global asthma budget (∼50%) due to unscheduled health care utilization in primary care, hospitalizations due to severe exacerbations, and the costs of pharmacotherapy. A key challenge in managing severe asthma is to identify appropriate groups of patients that will respond best to existing and evolving therapies. Recent advances in our understanding of how to classify severe asthma using multivariate taxonomical approaches have provided a unique model of a stratified medicines approach. For example, patients with inflammation-predominant asthma with eosinophils benefit from both inhaled and oral corticosteroids as well as targeted biologics such as anti-interleukin (IL)-5, all of which significantly reduce asthma exacerbations. On the other hand, patients with noneosinophilic neutrophilic asthma may be more suitable for steroid down-titration and therapeutic trials of antineutrophilic agents such as macrolide antibiotics. A similar paradigm can be applied to other domains in severe asthma such as airway hyperresponsiveness, which may now be treated with the first mechanical therapy in airways disease (bronchial thermoplasty). At the same time it is important for the clinician to recognize and treat comorbid factors that make asthma difficult to manage such as poor adherence to medication, rhinosinusitis, and psychological comorbidity. Therefore it is of vital importance to develop a multidisciplinary approach to the management of severe asthma that is best applied within specialist centers with experience and wider access to national and international severe asthma networks.

• References

• 1 Masoli M, Fabian D, Holt S, Beasley R ; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59 (5) 469-478
  CrossrefPubMedGoogle Scholar
• 2 Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005; 172 (2) 149-160
  CrossrefPubMedGoogle Scholar
• 3 Chanez P, Wenzel SE, Anderson GP , et al. Severe asthma in adults: what are the important questions?. J Allergy Clin Immunol 2007; 119 (6) 1337-1348
  CrossrefPubMedGoogle Scholar
• 4 Moore WC, Bleecker ER, Curran-Everett D , et al; National Heart, Lung, Blood Institute's Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119 (2) 405-413
  CrossrefPubMedGoogle Scholar
• 5 Bousquet J, Mantzouranis E, Cruz AA , et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126 (5) 926-938
  CrossrefPubMedGoogle Scholar
• 6 Chung KF, Godard P, Adelroth E , et al; European Respiratory Society. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. Eur Respir J 1999; 13 (5) 1198-1208
  PubMedGoogle Scholar
• 7 American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162 (6) 2341-2351
  CrossrefPubMedGoogle Scholar
• 8 Global Initiative for Asthma Guidelines. 2008. Global strategy for asthma management and prevention. http://www ginasthma com . Accessed January 7, 2008
  PubMedGoogle Scholar
• 9 Chanez P, Wenzel SE, Anderson GP , et al. Severe asthma in adults: what are the important questions?. J Allergy Clin Immunol 2007; 119 (6) 1337-1348
  CrossrefPubMedGoogle Scholar
• 10 Nathan RA, Sorkness CA, Kosinski M , et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113 (1) 59-65
  CrossrefPubMedGoogle Scholar
• 11 Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14 (4) 902-907
  CrossrefPubMedGoogle Scholar
• 12 Peters D, Chen C, Markson LE, Allen-Ramey FC, Vollmer WM. Using an asthma control questionnaire and administrative data to predict health-care utilization. Chest 2006; 129 (4) 918-924
  CrossrefPubMedGoogle Scholar
• 13 Thomas M, Gruffydd-Jones K, Stonham C, Ward S, Macfarlane TV. Assessing asthma control in routine clinical practice: use of the Royal College of Physicians ‘3 questions’. Prim Care Respir J 2009; 18 (2) 83-88
  PubMedGoogle Scholar
• 14 LeBlanc A, Robichaud P, Lacasse Y, Boulet LP. Quantification of asthma control: validation of the Asthma Control Scoring System. Allergy 2007; 62 (2) 120-125
  PubMedGoogle Scholar
• 15 Miller MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel SE ; TENOR Study Group. Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol 2005; 116 (5) 990-995
  CrossrefPubMedGoogle Scholar
• 16 Dolan CM, Fraher KE, Bleecker ER , et al; TENOR Study Group. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92 (1) 32-39
  CrossrefPubMedGoogle Scholar
• 17 European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22 (3) 470-477
  CrossrefPubMedGoogle Scholar
• 18 Cowburn AS, Sladek K, Soja J , et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101 (4) 834-846
  CrossrefPubMedGoogle Scholar
• 19 Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM ; British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010; 65 (9) 787-794
  CrossrefPubMedGoogle Scholar
• 20 Wardlaw AJ, Silverman M, Siva R, Pavord ID, Green R. Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 2005; 35 (10) 1254-1262
  CrossrefPubMedGoogle Scholar
• 21 Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372 (9643) 1107-1119
  CrossrefPubMedGoogle Scholar
• 22 Lötvall J, Akdis CA, Bacharier LB , et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127 (2) 355-360
  CrossrefPubMedGoogle Scholar
• 23 Haldar P, Pavord ID, Shaw DE , et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178 (3) 218-224
  CrossrefPubMedGoogle Scholar
• 24 Haldar P, Brightling CE, Hargadon B , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360 (10) 973-984
  CrossrefPubMedGoogle Scholar
• 25 Green RH, Brightling CE, McKenna S , et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360 (9347) 1715-1721
  CrossrefPubMedGoogle Scholar
• 26 Woodruff PG, Modrek B, Choy DF , et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180 (5) 388-395
  CrossrefPubMedGoogle Scholar
• 27 Moore WC, Meyers DA, Wenzel SE , et al; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181 (4) 315-323
  CrossrefPubMedGoogle Scholar
• 28 Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy 2009; 39 (11) 1652-1658
  CrossrefPubMedGoogle Scholar
• 29 Pavord ID, Wardlaw AJ. The A to E of airway disease. Clin Exp Allergy 2010; 40 (1) 62-67
  PubMedGoogle Scholar
• 30 Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004; 292 (3) 367-376
  CrossrefPubMedGoogle Scholar
• 31 Bateman ED, Boushey HA, Bousquet J , et al; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170 (8) 836-844
  CrossrefPubMedGoogle Scholar
• 32 Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM ; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129 (1) 15-26
  CrossrefPubMedGoogle Scholar
• 33 Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010; 65 (1) 39-43
  CrossrefPubMedGoogle Scholar
• 34 US Food and Drug Administration. Long-Acting Beta-Agonists (LABAs): New Safe Use Requirements. Silver Spring, MD: FDA; 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm201003.htm . Accessed October 22, 2010
  PubMedGoogle Scholar
• 35 van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9 (8) 1684-1688
  CrossrefPubMedGoogle Scholar
• 36 Baraniuk JN, Ali M, Brody D , et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997; 155 (2) 704-710
  CrossrefPubMedGoogle Scholar
• 37 Bateman ED, Harrison TW, Quirce S , et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res 2011; 12: 38
  CrossrefPubMedGoogle Scholar
• 38 Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357 (9273) 2007-2011
  CrossrefPubMedGoogle Scholar
• 39 Storms W, Michele TM, Knorr B , et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001; 31 (1) 77-87
  CrossrefPubMedGoogle Scholar
• 40 Micheletto C, Visconti M, Tognella S, Facchini FM, Dal Negro RW. Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. Eur Ann Allergy Clin Immunol 2006; 38 (1) 20-23
  PubMedGoogle Scholar
• 41 Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009; 3 (5) 235-243
  CrossrefPubMedGoogle Scholar
• 42 Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004; (3) CD003269
  PubMedGoogle Scholar
• 43 Peters SP, Kunselman SJ, Icitovic N , et al; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363 (18) 1715-1726
  CrossrefPubMedGoogle Scholar
• 44 Kerstjens HA, Disse B, Schröder-Babo W , et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128 (2) 308-314
  CrossrefPubMedGoogle Scholar
• 45 Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52 (6) 498-501
  CrossrefPubMedGoogle Scholar
• 46 Pizzichini E, Pizzichini MM, Leigh R, Djukanović R, Sterk PJ. Safety of sputum induction. Eur Respir J Suppl 2002; 37: 9s-18s
  PubMedGoogle Scholar
• 47 Efthimiadis A, Spanevello A, Hamid Q , et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002; 37: 19s-23s
  PubMedGoogle Scholar
• 48 Keatings VM, Evans DJ, O'Connor BJ, Barnes PJ. Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax 1997; 52 (4) 372-374
  CrossrefPubMedGoogle Scholar
• 49 Pizzichini E, Pizzichini MM, Kidney JC , et al. Induced sputum, bronchoalveolar lavage and blood from mild asthmatics: inflammatory cells, lymphocyte subsets and soluble markers compared. Eur Respir J 1998; 11 (4) 828-834
  CrossrefPubMedGoogle Scholar
• 50 Keatings VM, Evans DJ, O'Connor BJ, Barnes PJ. Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax 1997; 52 (4) 372-374
  CrossrefPubMedGoogle Scholar
• 51 Meijer RJ, Postma DS, Kauffman HF, Arends LR, Koëter GH, Kerstjens HA. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002; 32 (7) 1096-1103
  CrossrefPubMedGoogle Scholar
• 52 Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 2000; 55 (3) 232-234
  CrossrefPubMedGoogle Scholar
• 53 Meijer RJ, Postma DS, Kauffman HF, Arends LR, Koëter GH, Kerstjens HA. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002; 32 (7) 1096-1103
  CrossrefPubMedGoogle Scholar
• 54 Leuppi JD, Salome CM, Jenkins CR , et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163 (2) 406-412
  CrossrefPubMedGoogle Scholar
• 55 Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161 (1) 64-72
  CrossrefPubMedGoogle Scholar
• 56 Jayaram L, Pizzichini MM, Cook RJ , et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27 (3) 483-494
  CrossrefPubMedGoogle Scholar
• 57 Chlumský J, Striz I, Terl M, Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006; 34 (2) 129-139
  CrossrefPubMedGoogle Scholar
• 58 Petsky HL, Cates CJ, Lasserson TJ , et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67 (3) 199-208
  CrossrefPubMedGoogle Scholar
• 59 Flood-Page P, Swenson C, Faiferman I , et al; International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176 (11) 1062-1071
  CrossrefPubMedGoogle Scholar
• 60 Nair P, Pizzichini MM, Kjarsgaard M , et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360 (10) 985-993
  CrossrefPubMedGoogle Scholar
• 61 Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000; (2) CD000391
  PubMedGoogle Scholar
• 62 Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336 (8708) 137-140
  CrossrefPubMedGoogle Scholar
• 63 Domingo C, Moreno A, Amengual MJ, Comet R, Luján M. Twelve years' experience with methotrexate for GINA treatment step 5 asthma patients. Curr Med Res Opin 2009; 25 (2) 367-374
  CrossrefPubMedGoogle Scholar
• 64 Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119 (5) 1329-1336
  CrossrefPubMedGoogle Scholar
• 65 Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57 (10) 875-879
  CrossrefPubMedGoogle Scholar
• 66 Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160 (5 Pt 1) 1532-1539
  CrossrefPubMedGoogle Scholar
• 67 Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. Chest 2001; 120 (6) 1917-1922
  CrossrefPubMedGoogle Scholar
• 68 Shaw DE, Berry MA, Hargadon B , et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 2007; 132 (6) 1871-1875
  CrossrefPubMedGoogle Scholar
• 69 Busacker A, Newell Jr JD, Keefe T , et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009; 135 (1) 48-56
  CrossrefPubMedGoogle Scholar
• 70 Scott HA, Gibson PG, Garg ML, Wood LG. Airway inflammation is augmented by obesity and fatty acids in asthma. Eur Respir J 2011; 38 (3) 594-602
  CrossrefPubMedGoogle Scholar
• 71 Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010; 65 (5) 384-390
  CrossrefPubMedGoogle Scholar
• 72 Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; 62 (3) 211-218
  CrossrefPubMedGoogle Scholar
• 73 Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009; 33 (1) 171-181
  CrossrefPubMedGoogle Scholar
• 74 Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177 (2) 148-155
  CrossrefPubMedGoogle Scholar
• 75 Rosenstreich DL, Eggleston P, Kattan M , et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997; 336 (19) 1356-1363
  CrossrefPubMedGoogle Scholar
• 76 O'Hollaren MT, Yunginger JW, Offord KP , et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991; 324 (6) 359-363
  CrossrefPubMedGoogle Scholar
• 77 Targonski PV, Persky VW, Ramekrishnan V. Effect of environmental molds on risk of death from asthma during the pollen season. J Allergy Clin Immunol 1995; 95 (5 Pt 1) 955-961
  CrossrefPubMedGoogle Scholar
• 78 Black PN, Udy AA, Brodie SM. Sensitivity to fungal allergens is a risk factor for life-threatening asthma. Allergy 2000; 55 (5) 501-504
  CrossrefPubMedGoogle Scholar
• 79 Bush RK, Swenson C, Fahlberg B , et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011; 127 (4) 974-981 , e1–e7
  CrossrefPubMedGoogle Scholar
• 80 Humbert M, Beasley R, Ayres J , et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60 (3) 309-316
  CrossrefPubMedGoogle Scholar
• 81 Busse WW, Massanari M, Kianifard F, Geba GP. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Curr Med Res Opin 2007; 23 (10) 2379-2386
  CrossrefPubMedGoogle Scholar
• 82 O'Driscoll BR, Powell G, Chew F , et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009; 39 (11) 1677-1683
  CrossrefPubMedGoogle Scholar
• 83 Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110 (5) 685-692
  CrossrefPubMedGoogle Scholar
• 84 Fairs A, Wardlaw AJ, , Thompson Jr, Pashley CH. Guidelines on ambient intramural airborne fungal spores. J Investig Allergol Clin Immunol 2010; 20 (6) 490-498
  PubMedGoogle Scholar
• 85 Fairs A, Agbetile J, Hargadon B , et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010; 182 (11) 1362-1368
  CrossrefPubMedGoogle Scholar
• 86 Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27 (3) 615-626
  CrossrefPubMedGoogle Scholar
• 87 Denning DW, O'Driscoll BR, Powell G , et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179 (1) 11-18
  CrossrefPubMedGoogle Scholar
• 88 Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004; (3) CD001108
  PubMedGoogle Scholar
• 89 Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ ; The AMPUL Study Group. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999; 159 (4 Pt 1) 1043-1051
  CrossrefPubMedGoogle Scholar
• 90 Danek CJ, Lombard CM, Dungworth DL , et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol 2004; 97 (5) 1946-1953
  CrossrefPubMedGoogle Scholar
• 91 Miller JD, Cox G, Vincic L, Lombard CM, Loomas BE, Danek CJ. A prospective feasibility study of bronchial thermoplasty in the human airway. Chest 2005; 127 (6) 1999-2006
  CrossrefPubMedGoogle Scholar
• 92 Pavord ID, Cox G, Thomson NC , et al; RISA Trial Study Group. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007; 176 (12) 1185-1191
  CrossrefPubMedGoogle Scholar
• 93 Castro M, Rubin AS, Laviolette M , et al; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181 (2) 116-124
  CrossrefPubMedGoogle Scholar
• 94 Siddiqui S, Mistry V, Doe C , et al. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol 2008; 122 (2) 335-341 , 341, e1–e3
  CrossrefPubMedGoogle Scholar
• 95 Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346 (22) 1699-1705
  CrossrefPubMedGoogle Scholar
• 96 Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008; 121 (1) 5-10 , quiz 11–12
  CrossrefPubMedGoogle Scholar
• 97 Berry MA, Hargadon B, Shelley M , et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354 (7) 697-708
  CrossrefPubMedGoogle Scholar
• 98 Wenzel SE, Barnes PJ, Bleecker ER , et al; T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179 (7) 549-558
  CrossrefPubMedGoogle Scholar
• 99 Saha SK, Berry MA, Parker D , et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008; 121 (3) 685-691
  CrossrefPubMedGoogle Scholar
• 100 Taube C, Wei X, Swasey CH , et al. Mast cells, Fc epsilon RI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant. J Immunol 2004; 172 (10) 6398-6406
  PubMedGoogle Scholar
• 101 Corren J, Busse W, Meltzer EO , et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181 (8) 788-796
  CrossrefPubMedGoogle Scholar
• 102 Gupta S, Siddiqui S, Haldar P , et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136 (6) 1521-1528
  CrossrefPubMedGoogle Scholar
• 103 Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110 (5) 685-692
  CrossrefPubMedGoogle Scholar
• 104 Aysola RS, Hoffman EA, Gierada D , et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008; 134 (6) 1183-1191
  CrossrefPubMedGoogle Scholar
• 105 Siddiqui S, Gupta S, Cruse G , et al. Airway wall geometry in asthma and nonasthmatic eosinophilic bronchitis. Allergy 2009; 64 (6) 951-958
  CrossrefPubMedGoogle Scholar
• 106 Gupta S, Siddiqui S, Haldar P , et al. Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax 2010; 65 (9) 775-781
  CrossrefPubMedGoogle Scholar
• 107 Mastronarde JG, Anthonisen NR, Castro M , et al; American Lung Association Asthma Clinical Research Centers. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360 (15) 1487-1499
  CrossrefPubMedGoogle Scholar
• 108 Kiljander TO, Junghard O, Beckman O, Lind T. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2010; 181 (10) 1042-1048
  CrossrefPubMedGoogle Scholar
• 109 Kiljander TO, Harding SM, Field SK , et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173 (10) 1091-1097
  CrossrefPubMedGoogle Scholar
• 110 Stelmach R, do Patrocínio T Nunes M, Ribeiro M, Cukier A. Effect of treating allergic rhinitis with corticosteroids in patients with mild-to-moderate persistent asthma. Chest 2005; 128 (5) 3140-3147
  CrossrefPubMedGoogle Scholar
• 111 Sin DD, Sutherland ER. Obesity and the lung, IV: Obesity and asthma. Thorax 2008; 63 (11) 1018-1023
  CrossrefPubMedGoogle Scholar
• 112 Julien JY, Martin JG, Ernst P , et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol 2009; 124 (2) 371-376
  CrossrefPubMedGoogle Scholar
• 113 Eneli IU, Skybo T, Camargo Jr CA. Weight loss and asthma: a systematic review. Thorax 2008; 63 (8) 671-676
  CrossrefPubMedGoogle Scholar
• 114 Thomas M, McKinley RK, Freeman E, Foy C. Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey. BMJ 2001; 322 (7294) 1098-1100
  CrossrefPubMedGoogle Scholar
• 115 Thomas M, McKinley RK, Freeman E, Foy C, Price D. The prevalence of dysfunctional breathing in adults in the community with and without asthma. Prim Care Respir J 2005; 14 (2) 78-82
  CrossrefPubMedGoogle Scholar
• 116 Thomas M, McKinley RK, Mellor S , et al. Breathing exercises for asthma: a randomised controlled trial. Thorax 2009; 64 (1) 55-61
  PubMedGoogle Scholar
• 117 Alvarez GG, Fitzgerald JM. A systematic review of the psychological risk factors associated with near fatal asthma or fatal asthma. Respiration 2007; 74 (2) 228-236
  CrossrefPubMedGoogle Scholar
• 118 Heaney LG, Conway E, Kelly C, Gamble J. Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome. Respir Med 2005; 99 (9) 1152-1159
  CrossrefPubMedGoogle Scholar
• 119 Fagan J, Galea S, Ahern J, Bonner S, Vlahov D. Relationship of self-reported asthma severity and urgent health care utilization to psychological sequelae of the September 11, 2001 terrorist attacks on the World Trade Center among New York City area residents. Psychosom Med 2003; 65 (6) 993-996
  CrossrefPubMedGoogle Scholar
• 120 Brown ES, Khan DA, Mahadi S. Psychiatric diagnoses in inner city outpatients with moderate to severe asthma. Int J Psychiatry Med 2000; 30 (4) 319-327
  PubMedGoogle Scholar
• 121 Valença AM, Falcão R, Freire RC , et al. The relationship between the severity of asthma and comorbidities with anxiety and depressive disorders. Rev Bras Psiquiatr 2006; 28 (3) 206-208
  CrossrefPubMedGoogle Scholar
• 122 Smith JR, Mugford M, Holland R, Noble MJ, Harrison BD. Psycho-educational interventions for adults with severe or difficult asthma: a systematic review. J Asthma 2007; 44 (3) 219-241
  CrossrefPubMedGoogle Scholar
• 123 Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180 (9) 817-822
  CrossrefPubMedGoogle Scholar
• 124 Cohen JL, Mann DM, Wisnivesky JP , et al. Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol 2009; 103 (4) 325-331
  CrossrefPubMedGoogle Scholar
• 125 Haupt D, Nilsson JL. Asthma medication - persistence with adrenergics, steroids and combination products over a 5-year period. J Clin Pharm Ther 2009; 34 (5) 507-513
  CrossrefPubMedGoogle Scholar
• 126 Bae YJ, Kim TB, Jee YK , et al. Severe asthma patients in Korea overestimate their adherence to inhaled corticosteroids. J Asthma 2009; 46 (6) 591-595
  CrossrefPubMedGoogle Scholar
• 127 Ponieman D, Wisnivesky JP, Leventhal H, Musumeci-Szabó TJ, Halm EA. Impact of positive and negative beliefs about inhaled corticosteroids on adherence in inner-city asthmatic patients. Ann Allergy Asthma Immunol 2009; 103 (1) 38-42
  CrossrefPubMedGoogle Scholar
• 128 Janson SL, McGrath KW, Covington JK, Cheng SC, Boushey HA. Individualized asthma self-management improves medication adherence and markers of asthma control. J Allergy Clin Immunol 2009; 123 (4) 840-846
  CrossrefPubMedGoogle Scholar
• 129 Strandbygaard U, Thomsen SF, Backer V. A daily SMS reminder increases adherence to asthma treatment: a three-month follow-up study. Respir Med 2010; 104 (2) 166-171
  CrossrefPubMedGoogle Scholar
• 130 Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RM. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 2004; 98 (8) 752-759
  CrossrefPubMedGoogle Scholar
• 131 Breekveldt-Postma NS, Koerselman J, Erkens JA, van der Molen T, Lammers JW, Herings RM. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf 2008; 17 (4) 411-422
  CrossrefPubMedGoogle Scholar
• 132 Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343 (5) 332-336
  CrossrefPubMedGoogle Scholar
• 133 Lehane E, McCarthy G. An examination of the intentional and unintentional aspects of medication non-adherence in patients diagnosed with hypertension. J Clin Nurs 2007; 16 (4) 698-706
  CrossrefPubMedGoogle Scholar
• 134 ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. “Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170 (6) 601-605
  CrossrefPubMedGoogle Scholar